A Systematic Literature Review and Economic Evaluation with a Meta-Analysis of Randomized Control Trials Focusing on Symptom Reduction in Adults Ages 18 and Older Treated by Either Esomeprazole, Omeprazole, Lansoprazole, Rabeprazole, or Pantroprazole for Diagnosed Reflux Disease in North America and Europe

Document Type

Presentation

Loading...

Media is loading
 

Publication Date

7-18-2018

Comments

Presentation: 52:52

Abstract

This paper is a systematic literature review of Randomized Control Trials and Economic Evaluations focusing on symptom reduction in adults ages 18 and older treated by five branded Proton Pump Inhibitors for diagnosed Gastroesophageal Reflux Disease in North America and Europe. As the disease affects roughly 20-30% of people living in western countries regardless of age, an understanding of how to provide the best care using Proton Pump Inhibitors with consideration of clinical and economic outcomes is of vital importance. The purpose of this study is to compare the mean differences in intragastric pH values from day one to day five of the five proton pump inhibitors to answer which has the greatest efficacy. This paper will also focus on the estimated direct annual medical costs available for GERD.

Language

English

This document is currently not available here.

Submit Feedback on Presentation

Share

COinS